However, a high percentage of ERα+ breast cancers are de-novo (15–20%) or acquired resistance (30–40%) to endocrine therapy progressing from hormone dependence to independence, although a functional ERα pathway is still maintained [4,6,7]. The gene discussed is ESR1; the disease is breast carcinoma.